City of Hope researchers identify biomarkers that may detect risk of advanced prostate cancer in Black men

Cost of family insurance plans rose for workers in 2026, KFF survey finds

Premiums for family health insurance plans sponsored by employers have risen 9% from 2025 to 2026, according to the Kaiser Family Foundation’s annual survey of large and small employers.

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

October 30, 2026

Vol.52 No.40

Drugs & Targets

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

FDA has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, including both BRCA and non-BRCA mutations.

October 30, 2026

Vol.52 No.40

Capitol Hill

Iowa’s “cancer crisis” emerges as a top issue on the campaign trail

“As Iowa goes, so goes the nation.”

October 23, 2026

Vol.52 No.39

By Sara Willa Ernst

Moving beyond escalation to a new therapeutic strategy in oncology
Microbiome-based treatment may offer a different approach

Cancer therapy has become increasingly personalized. Biomarker-driven treatment selection, targeted therapies, and immunotherapy have transformed outcomes across many tumor types and demonstrated the power of matching the right treatment to the right patient.

October 23, 2026

Vol.52 No.39

By Sumanta Pal

City of Hope researchers identify biomarkers that may detect risk of advanced prostate cancer in Black men

YOU MAY BE INTERESTED IN

Cost of family insurance plans rose for workers in 2026, KFF survey finds

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

Iowa’s “cancer crisis” emerges as a top issue on the campaign trail

Moving beyond escalation to a new therapeutic strategy in oncology
Microbiome-based treatment may offer a different approach

Renew today!

Subscriber content

Never miss an issue!

Login

City of Hope researchers identify biomarkers that may detect risk of advanced prostate cancer in Black men

YOU MAY BE INTERESTED IN

Cost of family insurance plans rose for workers in 2026, KFF survey finds

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

Iowa’s “cancer crisis” emerges as a top issue on the campaign trail

Moving beyond escalation to a new therapeutic strategy in oncologyMicrobiome-based treatment may offer a different approach

Never miss an issue!

Login

Moving beyond escalation to a new therapeutic strategy in oncology
Microbiome-based treatment may offer a different approach